



SEQUENCE LISTING

<110> UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

<120> TAT AS AN IMMUNOGEN

<130> 050229-0444

<140> 10/506,408

<141> 2005-06-22

<150> PCT/US03/05806

<151> 2003-02-27

<150> US 60/361,043

<151> 2002-03-01

<160> 3

<170> PatentIn version 3.4

<210> 1

<211> 72

<212> PRT

<213> HIV

<400> 1

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr
50 55 60

His Gln Ala Ser Leu Ser Lys Gln
65 70

<210> 2

<211> 86

<212> PRT

<213> HIV

<400> 2

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
 20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
 35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr
 50 55 60

His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp
 65 70 75 80

Pro Thr Gly Pro Lys Glu
 85

<210> 3
 <211> 86
 <212> PRT
 <213> HIV

<220>
 <221> MUTATION
 <222> (22)..(22)
 <223> Cys 22 SUBSTITUTED FOR Gly

<400> 3

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
 1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Gly Tyr Cys Lys Lys Cys Cys Phe
 20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
 35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr
 50 55 60

His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp
 65 70 75 80

Pro Thr Gly Pro Lys Glu
 85